INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint....
Neuroscience
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with...
Neurophet to present brain stimulation simulation study at OHBM 2024
- Presents a poster identifying tDCS effects for patients with AD and cognitively normal people - Showcases brain imaging treatment planning...
AMSBIO and Bioz Combine Efforts to Empower the Scientific Community With Citation Data
PALO ALTO, CA / ACCESSWIRE / June 26, 2024 / Bioz, Inc., a pioneer in AI-driven research solutions, is delighted...
Linus Health Introduces Person-Centered Approach to Establish Clinically Meaningful Benefits and Personalized Brain Health Care
Scalable, systematic and automated process captures and monitors metrics based on patients' treatment priorities for managing Alzheimer's disease and related dementias...
NXTSTIM EcoAI™ using Novel Artificial Intelligence Machine Learning (AIML) Technology with Transcutaneous Nerve and Electromyographic Stimulation shows outstanding 18-month real-world outcomes data with a Remote Patient Monitoring platform (RPM)
SAN DIEGO, June 25, 2024 /PRNewswire/ -- NXTSTIM will present their 18-month real-world outcomes data using EcoAI™ at the American Society...
Zeto Announces Winners of Clinical Trial Sponsorship Program
SANTA CLARA, Calif., June 25, 2024 /PRNewswire/ -- Zeto, Inc., an award-winning medical technology firm, is proud to announce the...
BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose)...
Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis
OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV)...
SQUID pries open AI black box
COLD SPRING HARBOR, N.Y., June 21, 2024 /PRNewswire/ -- Artificial intelligence continues to squirm its way into many aspects of...
10x Genomics Begins Commercial Shipments of Xenium Prime 5K Pan-Tissue and Pathways Panel
New 5,000-plex gene panel increases plex by an order of magnitude and delivers industry-leading speed and throughput PLEASANTON, Calif., June 20,...
HealthTech Connex Awarded $1 Million from The Government of Canada to Revolutionize Concussion Detection and Recovery
The NeuroCatch Platform, a subsidiary of HealthTech Connex, offers an objective evaluation of cognitive function, delivered in minutes at the...
Can AI learn like us?
COLD SPRING HARBOR, N.Y., June 20, 2024 /PRNewswire/ -- It reads. It talks. It collates mountains of data and recommends...
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial
Parkinson’s Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients’ Own Autologous Replacement NeuronsSOLANA BEACH, Calif., June...
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain...
INSIGHTEC ANNOUNCES $150M FINANCING TO FUND CONTINUED GROWTH
Fidelity Management & Research Company Leads Financing; Nexus Neurotech Ventures and Ally Bridge Group Co-Lead Robust Investor Syndicate HAIFA, Israel...
BrainCheck and Alzheimer’s Association Partner to Present Live Panel Event on Advancements in Brain Health and Dementia Care
Moderated by Emmy award-winning Spectrum News 1 Anchor and National Mental Health Correspondent, Nicole Clark, Ph.D., panel to feature renowned experts...
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be...
Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024
BOSTON, June 18, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system...
Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting
Single Infusion of ANX005 Demonstrated Significant Improvements Across Multiple Functional and Prognostic Measures That Expedited Recovery in GBS Patients ANX005...